- GROUP Rare Cancers
- PROJECT SPAN 2022
- DATE 02/05/2022
The Australian Rare Cancer (ARC) Portal
The ARC Portal is a program under the AGCMC and supported by BioGrid Australia.
The Portal
It provides centralised (online) support for clinicians of patients including:
- Access to rare cancer guidelines or evidence
- Advice, in person or tele-consultations with national rare cancer experts
- Molecular testing advice (including via AGCMC/MoST) or help with interpretation of existing reports.
The ARC Portal also allows Australian patients with rare cancers to enrol into the Stafford Fox Rare Cancer Program to allow their deidentified clinical data (and optionally biospecimens) to be used for research. All Australian researchers can access these resources for approved projects. By providing patients broader access to research we will accelerate our understanding of individual rare cancers and improved the feasibility of performing rare cancer research in Australia.
The ARC Portal can be found at: www.arcportal.org.au
Join Australia's leading oncology community & make an impact
Become a COSA memberTwitter
@COSAoncology
Follow
![](/Frontend/Images/smlogo.png)
COSAoncology 2 days ago
Thank you @HGSAAustralasia for maintaining Affiliated membership and continuing to collaborate with COSA to improve cancer care and control. Members of HGSA can join COSA at a discounted rate. Join or renew here: bit.ly/3s5mOC6
Read More >![](/Frontend/Images/smlogo.png)
COSAoncology 2 days ago
We are pleased that @dietitiansaus continue to be an Associated member organisation with COSA, and look forward to our ongoing collaboration to improve cancer care and control. DA members can join COSA at a discounted rate. Join or renew here: bit.ly/3s5mOC6
Read More >![](/Frontend/Images/smlogo.png)
COSAoncology 4 days ago
We are pleased that @anzgog continue to be an Affiliated member organisation with COSA, and look forward to our ongoing collaboration to improve cancer care and control. ANZGOG members can join COSA at a discounted rate. Join or renew here: bit.ly/3s5mOC6
Read More >![](/Frontend/Images/smlogo.png)
COSAoncology 4 days ago
We are pleased that @anzgog continue to be an Affiliated member organisation with COSA, and look forward to our ongoing collaboration to improve cancer care and control. ANZGOG members can join COSA at a discounted rate. Join or renew here: bit.ly/3s5mOC6
Read More >![](/Frontend/Images/smlogo.png)
COSAoncology 4 days ago
Thank you @ALLGtrials for maintaining Affiliated membership and continuing to collaborate with COSA to improve cancer care and control. Members of ALLG can join COSA at a discounted rate. Join or renew here: bit.ly/3s5mOC6
Read More >![](/Frontend/Images/smlogo.png)
COSAoncology 25 days ago
We are pleased that @OSWA_Australia continue to be an Affiliated member organisation with COSA, and look forward to our ongoing collaboration to improve cancer care and control. OSWANZ members can join COSA at a discounted rate. Join or renew here: bit.ly/3s5mOC6
Read More >![](/Frontend/Images/smlogo.png)
COSAoncology one month ago
Thank you @RANZCRcollege for maintaining Affiliated membership and continuing to collaborate with COSA to improve cancer care and control. Members of RANZCR can join COSA at a discounted rate. Join or renew here: bit.ly/3s5mOC6
Read More >![](/Frontend/Images/smlogo.png)
COSAoncology one month ago
We are pleased that @PathologyRCPA continue to be an Affiliated member organisation with COSA, and look forward to our ongoing collaboration to improve cancer care and control. RCPA members can join COSA at a discounted rate. Join or renew here: bit.ly/3s5mOC6
Read More >![](/Frontend/Images/smlogo.png)
COSAoncology one month ago
COSA members on automatic renewal, don't forget to update your billing details before 1 July 2024! Login to the COSA website and go to My Membership, Billing Information: bit.ly/4cI0nc3
Read More >![](/Frontend/Images/smlogo.png)
COSAoncology one month ago
Do you prefer to pay membership fees prior to end of financial year? Now is the time to renew your COSA membership: bit.ly/4cI0nc3
Read More >